
Going anti-Viral
Introducing Going anti-Viral, the podcast of the IAS–USA, a professional continuing medical education organization focused on HIV and other viral diseases. I’m Dr Michael Saag, professor emeritus of medicine and infectious diseases at the University of Alabama at Birmingham and volunteer member of the IAS–USA Board of Directors.
Join us as we interview experts in viral medicine about their area of specialty and current developments in the field. Other episodes are drawn from the IAS-USA vast catalogue of panel discussions, Dialogues, and various meetings and conferences.
Going anti-Viral is a podcast series for clinicians, produced by the International Antiviral Society–USA. The IAS–USA is a not-for-profit professional organization committed to improving the treatment, care, and quality of life for people with or at risk for HIV or other viral infections and their complications through balanced education and information. This podcast is intended as a clinical source of information for specialists in this field, but we hope anyone listening will enjoy learning more about the state of modern medicine around viral infections and their consequences.
Going anti-Viral
Episode 44 – IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1 – Dr Annemarie Wensing
In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Annemarie M. Wensing, a Clinical Virologist at the University Medical Center Utrecht and an Honorary Professor at the University of the Witwatersrand in Johannesburg. Dr Wensing joins Dr Saag to discuss the recently released IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1. Dr Wensing discusses the influence of Dr Charles Boucher in developing her interest in the topic of HIV drug resistance and Dr Wensing and Dr Saag provide an overview of HIV drug resistance and testing. Dr Wensing also provides advice to clinicians on how to manage patients who experience drug resistance. Dr Wensing and Dr Saag then discuss an upcoming report soon to be published that addresses the potential role and the important limitations of HIV DNA resistance testing. Finally, they address the topic of drug resistance in the absence of resistance mutations and look ahead to what the future holds for the field of HIV resistance.
0:00 – Introduction
1:30 – Dr Wensing reviews the influence that Dr Charles Boucher played in her development as an investigator and her interest in HIV resistance
2:46 – Discussion of why there is HIV drug resistance
4:48 – Overview of drug resistance testing, genotypes and phenotypes
7:25 – New recommendations from the IAS-USA resistance mutation panel
9:50 – Advice to clinicians on managing drug resistance
16:16 – Discussion of HIV DNA resistance testing
21:26 – Understanding drug failure in the absence of resistance mutations
24:49 – Predictions about the future
Resources:
- IAS–USA Drug Resistance Mutations Chart: https://www.iasusa.org/hiv-drug-resistance/hiv-drug-resistance-mutations/
__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.
Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
X
Facebook
Instagram
...